The ABHD5 Knockout HT29 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal population derived from HT29 human colorectal adenocarcinoma epithelial cells, featuring a targeted disruption of the ABHD5 gene. This loss-of-function model abolishes the expression of the ABHD5 protein (also known as CGI-58), a critical coactivator of intracellular lipolysis, providing researchers with a robust tool to dissect lipid metabolic pathways in a cancer-relevant cellular context.
The HT29 host cell line was originally isolated from a primary colorectal adenocarcinoma of a 44-year-old female and displays epithelial morphology. Widely employed as a model for the intestinal epithelial barrier and colorectal cancer biology, HT29 cells exhibit hallmark features such as polarization, tight junction formation, and characteristic metabolic dependencies, making them suitable for investigating the intersection of lipid metabolism and tumor cell physiology.
At the molecular level, ABHD5 resides on the surface of lipid droplets and serves as an essential coactivator of adipose triglyceride lipase (ATGL/PNPLA2), the rate-limiting enzyme for triglyceride hydrolysis. The canonical lipolytic cascade is initiated by beta-adrenergic receptor stimulation, leading to Gs-protein-coupled adenylate cyclase activation, elevation of cyclic AMP, and protein kinase A-mediated phosphorylation of perilipin-1 (PLIN1). This event releases ABHD5 from PLIN1, permitting its interaction with ATGL and subsequent catabolism of triglycerides into diacylglycerol and free fatty acids. ABHD5 function is further modulated by interactions with perilipin-2 (PLIN2) and perilipin-5 (PLIN5), and integrates inputs from insulin signaling and the PPAR??/PPAR?? transcriptional regulators.
In the context of HT29 cells, which rely on lipid metabolism for energy production, membrane biosynthesis, and signaling, ABHD5 knockout disrupts the mobilization of stored triglycerides, resulting in aberrant lipid droplet accumulation and altered fatty acid flux. This phenotypic change mimics aspects of neutral lipid storage disorders, such as Chanarin-Dorfman syndrome, and reflects the metabolic reprogramming often observed in colorectal cancer, positioning this model as a valuable system to explore how dysregulated lipolysis contributes to tumorigenesis and epithelial barrier dysfunction.
This knockout cell population supports a broad array of experimental applications, including lipid droplet visualization by BODIPY 493/503 or Oil Red O staining, quantification of triglyceride levels and free fatty acid release, metabolic flux analysis using Seahorse technology, and assessment of cell proliferation and viability under lipotoxic or nutrient-deprived conditions. The model is also suitable for co-immunoprecipitation studies to probe ABHD5-ATGL interactions, RNA-seq-based transcriptomic profiling of metabolic gene networks, and drug sensitivity screening targeting lipolytic pathways or lipid storage disorders. For technical inquiries, please contact Ascent Research.
